Outlook Therapeutics to Participate in Cantor Fitzgerald’s Virtual Panel Discussion: Eyeing Key Events and Programs in the ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late
clinical-stage biopharmaceutical company working to develop the
first FDA-approved ophthalmic formulation of bevacizumab-vikg for
use in retinal indications, today announced that Lawrence A.
Kenyon, President, CEO and CFO of Outlook Therapeutics, will
participate in the Cantor Fitzgerald “Eyeing Key Events and
Programs in the Ophthalmology Space in 2021” virtual panel being
held on Friday, February 19, 2021 from 10:30 AM – 12:00 PM ET.
The panel, hosted by Kristen Kluska, Equity
Research Analyst at Cantor Fitzgerald, will discuss market
opportunities across numerous indications in the ophthalmology
space and will include highlights from participating company
pipelines, previously reported datasets, and upcoming 2021
milestones and events.
To attend the virtual panel, please register in advance
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage
biopharmaceutical company working to develop ONS-5010/LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab-vikg for use in retinal indications, including wet
AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics
expects to commercialize it as the first and only FDA-approved
ophthalmic formulation of bevacizumab-vikg for use in treating a
range of retinal diseases in the United States, United Kingdom,
Europe, Japan, China and other markets. Outlook Therapeutics
expects to file ONS-5010 with the U.S. FDA as a new BLA under the
PHSA 351(a) regulatory pathway, initially for wet AMD. For more
information, please visit www.outlooktherapeutics.com.
Media Inquiries:Harriet UllmanAssistant Vice
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com